M. Mosca (Pisa), R. Perricone (Roma) - Sir

132 A. Martini, C. Malattia
5. Gattorno M, Piccini A, Lasigliè D, et al. The pattern of
response to anti IL-1 treatment distinguishes two subset
of patients with systemic onset juvenile idiopathic
arthritis. Arthritis Rheum 2008; 58: 1505-15.
6. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary
diagnostic guidelines for macrophage activation
sindrome complicating systemic juvenile idiopathic
arthritis. J Pediatr 2005; 146: 598-604.
7. Janka G, Zur Stadt U. Familial and acquired hemophagocytic
lymphohistiocytosis. Hematology Am Soc
Hematol Educ Program 2005; 82-8.
8. Grom AA. Natural killer cell dysfunction: A common
pathway in systemic-onset juvenile rheumatoid arthritis,
macrophage activation syndrome, and hemophago-
cytic lymphohistiocytosis? Arthritis Rheum. 2004; 50:
689-98.
9. Parodi A, Davì S, Pringe AB, et al. Macrophage activation
syndrome in juvenile systemic lupus erythematosus
A multinational multicenter study of 38 patients.
Arthritis Rheum in press.
10. Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage
activation syndrome in systemic juvenile rheumatoid
arthritis successfully treated with cyclosporine.
J Pediatr 1996; 128: 275-78.
11. Mouy R, Stephan J-L, Pillet P, et al. Efficacy of cyclosporine
A in the treatment of macrophage activation
syndrome in juvenile arthritis: report of five cases. J Pediatr
1996, 129: 750-4.